Epilepsy Study -- 718.246.8614

The Comprehensive Epilepsy Center in New York Methodist Hospital is recruiting patients for a Phase 3b/4 clinical research study with Lacosamide (Vimpat).

The study is an open-label, multicenter, multinational trial of Lacosamide (Vimpat) in subjects with partial onset seizures. 130 centers are involved worldwide and our Epilepsy Center is only one of two sites in New York.

Lacosamide has already been approved by the US Food and Drug Administration (FDA) for the treatment of partial-onset seizures. For purposes of this study, Lacosamide will be treated as an investigational drug.

The objective of the study is to evaluate the efficacy and safety of oral Vimpat as first add-on treatment in subjects with uncontrolled partial-onset seizures (with or without secondary generalization) after treatment with first AED monotherapy regimen, compared to subjects with uncontrolled partial-onset seizures (with or without secondary generalization) despite treatment with at least two Antiepileptic Drugs (AED).

We are seeking participants who:

• Are 17 to 65 years of age
• Have a diagnosis of refractory partial seizures 
• Are not controlled despite being on 1 or more antiepileptic drugs 
• Have at least 1 seizure in each of the 3 months immediately prior to screening
• Have seizures that are countable, not clustered

And belong to one of the following two groups:

• Diagnosis < 1 year, on 1 AED, having > 1 and < 40 seizures/ month
• Diagnosis > 5 years, on 1-3 AEDs, having > 1 and < 40 seizures/month

Participants who qualify will receive, all at no charge:

• Study-related medical care
• Laboratory work and evaluation 
• Vimpat (Lacosamide) 
• Travel Reimbursement

For more details on the study, call 718 246 8614.